Log in
Get started
Product
Case Studies
Security
About
Blog
FAQ
Get started
Log in
Request Early Access
Sign up for Early Access of the DeepMirror App
Work Email
Organisation Type
Please select...
Industry
Academia
Where did you hear about us and what would you like to use the app for?
Submit
Request a Demo
Sign up for a demo of deepmirror
Work email
*
Organisation type
*
Select
Industry
Academia
Where did you hear about us and what would you like to use the app for?
Submit
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Blog
TIME Recognises Drug Design for Global Health (dd4gh) Among 2026’s Best Inventions
The Drug Design for Global Health (dd4gh) project, developed by deepmirror in partnership with Medicines for Malaria Venture (MMV), has been named on TIME’s Best Inventions of 2026 list in the Social Impact category.
deepmirror
Press Release
All
News
Case Study
Research
Learning
Use Case
Q&A: Jérémy Besnard
We’re delighted to announce that we have appointed a couple of senior industry figures to be deepmirror’s new scientific advisors. Today, we sit down with Jérémy Besnard, a co-founder of Exscientia, to find out why he’s joined the deepmirror journey:
deepmirror
News
Q&A: Mark Murcko
We’re delighted to announce that we have appointed a couple of senior industry figures to be deepmirror’s new scientific advisors. Today, we sit down with Mark Murcko, a senior lecturer at MIT and legendary drug-hunter, to find out why he’s joined the deepmirror journey:
deepmirror
News
TIME Recognises Drug Design for Global Health (dd4gh) Among 2026’s Best Inventions
The Drug Design for Global Health (dd4gh) project, developed by deepmirror in partnership with Medicines for Malaria Venture (MMV), has been named on TIME’s Best Inventions of 2026 list in the Social Impact category.
deepmirror
Press Release
Better, Safer, Faster, Cheaper: AI’s impact on drug design
What is the ROI of AI-driven drug discovery? Pharma R&D burns roughly $300 billion a year, about $6 billion per approved drug. AI today primarily impacts the speed at which drugs are developed, but today's models barely move the needle.
Max
Learning
£1M project on molecule data, backed by Sovereign AI grant from Innovate UK
deepmirror has been awarded a Phase 2 Sovereign AI grant as part of Innovate UK’s support for British businesses building world-leading AI technologies.
deepmirror
News
MMV and deepmirror announce $5 million grant for Drug Design for Global Health (dd4gh)
Medicines for Malaria Venture (MMV) and deepmirror have secured a $5 million grant from the Gates Foundation for the continuation of their partnership on Drug Design for Global Health (dd4gh), an AI-powered drug discovery platform.
deepmirror
News
60%+ Hit Rate from a Billion-Molecule Screen: Tes Pharma’s Results with deepmirror™
Tes Pharma achieved a hit rate exceeding 60% from a billion-scale virtual screen using deepmirror™. This result significantly outperforms typical hit rates of 5-10% for challenging transcription factor targets.
deepmirror
Case Study
Free AI drug discovery platform aims to level the playing field for global health research
Medicines for Malaria Venture and deepmirror launch open-access research platform designed to remove barriers for scientists, especially in low- and middle-income countries
deepmirror
Press Release
Toward Chemical Interpretability of AI-Predicted Poses
Cofolding models like AlphaFold3, OpenFold3, Boltz-2, and Chai-1 can generate protein–ligand complexes that look convincing but often break basic chemical rules. In this post, we describe how post-processing steps such as restoring bond types, hydrogens, and realistic geometry can make these AI-predicted poses chemically interpretable and ready for downstream modeling.
deepmirror
Learning
Next
1
...
1 / 5
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Stay in the loop!
We only send our newsletter every few months, so no inbox clutter.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Subscribe